Vol. 19, Issue 3, 2009January 01, 2009 EDT
Balancing on the Edge: The Implications and Acceptability of Off-Label Drug Use
Balancing on the Edge: The Implications and Acceptability of Off-Label Drug Use
Articles in Vol. 19, Issue 3, 2009
Vol. 19, Issue 3, 2009
- Considerations for the Off-Label Use of Medications in OncologySarah L. Scarpace
- Industry and Physicians, the Good, the Bad and the UglyDan R. Thompson
- Off-Label Use From Injured Consumers PerspectiveEric Chaffin
- Off-Label Drug Use: Pros and ConsBrian Kane
- Legal and Regulatory Commercial BattlesPatrick Igoe
- Promotion of Off-Label Use: In Favor of a Regulatory RetreatByron Stier
- Litigation Aspects of Off-Label Use: Quality of Care, Generally Accepted Medical Practices & Emergence of Cost ContainmentRaul A. Tabora Jr.
- FDAs Oversight of the Promotion of Drugs for Off-Label UsesMollie Hertel
- Balancing on the Edge: The Implications and Acceptability of Off-Label Drug UseDanielle Holley
Danielle Holley, Balancing on the Edge: The Implications and Acceptability of Off-Label Drug Use, 19 ALB. L.J. SCI. & TECH. (2009).